SCHEMBL4127825

SCHEMBL4127825

COc1cc(C)c(O)c(O)c1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
CYP3A4 P08684 1/20 0.54
EPHX2 P34913 3/20 0.51
ACHE P22303 1/20 0.50
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44
GRIN3A Q8TCU5 1/20 0.44
CA9 Q16790 2/20 0.43
FYN P06241 1/20 0.43
ALOX5 P09917 3/20 0.42
KDM4E B2RXH2 1/20 0.42
ABL1 P00519 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29421891 0.86 EPHX2 (0.57) MAPTCYP3A4EPHX2ACHECA9
SCHEMBL4472439 0.86 EPHX2 (0.57) MAPTCYP3A4EPHX2ACHECA9
SCHEMBL12587650 0.84 MAPT (0.52) MAPTCYP3A4EPHX2ACHEPTGS1
SCHEMBL1808984 0.82 EPHX2 (0.49) MAPTCYP3A4EPHX2ACHEPTGS2
SCHEMBL684134 0.82 MAPT (0.48) MAPTCYP3A4EPHX2ACHEPTGS1
SCHEMBL70823 0.81 MAPT (0.58) MAPTCYP3A4ACHEPTGS2GRIN2D
SCHEMBL5770364 0.81 MAPT (0.48) MAPTCYP3A4EPHX2ACHEPTGS1
SCHEMBL27497325 0.80 MAPT (0.64) MAPTCYP3A4EPHX2ACHEPTGS1
SCHEMBL24407972 0.79 CYP3A4 (0.47) MAPTCYP3A4EPHX2ACHEPTGS1
SCHEMBL30542065 0.79 TDP1 (0.52) MAPTCYP3A4EPHX2ALOX5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276107-A1 HYDROGEL SYSTEMS AND METHODS FOR TREATING FISTULA AND OTHER INDICATIONS TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION (US) 2025-09-04 US claimed
CN-109276563-B Application of pharmaceutical composition in preparing medicine for treating or preventing individual infection virus 珠海市鑫展生物科技有限公司 2021-04-09 CN claimed
US-3930862-A DYE DEVELOPER TRANSFER PHOTOSENSITIVE MATERIAL WITH SUBSTITUTED CATECHOL AUXILIARY DEVELOPER FUJI PHOTO FILM CO., LTD. (JA) 1976-01-06 US claimed
US-20250276107-A1 HYDROGEL SYSTEMS AND METHODS FOR TREATING FISTULA AND OTHER INDICATIONS TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION (US) 2025-09-04 US disclosed
CN-109276563-B Application of pharmaceutical composition in preparing medicine for treating or preventing individual infection virus 珠海市鑫展生物科技有限公司 2021-04-09 CN disclosed
CN-109276563-A Application of pharmaceutical composition in preparing medicine for treating or preventing individual infection virus 珠海市鑫展生物科技有限公司 2019-01-29 CN disclosed
US-20090137687-A1 Compositions and Methods With Enhanced Therapeutic Activity OXIGENE, INC. (US) 2009-05-28 US disclosed
US-3930862-A DYE DEVELOPER TRANSFER PHOTOSENSITIVE MATERIAL WITH SUBSTITUTED CATECHOL AUXILIARY DEVELOPER FUJI PHOTO FILM CO., LTD. (JA) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137687-A1 Compositions and Methods With Enhanced Therapeutic Activity NQO1, MKI67, COMT MAPT 4096/4885CYP3A4 561/4885EPHX2 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.